A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ivabradine (Corlanor)

Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker class · 6 generic manufacturers · 12 ANDAs filed at FDA.

First FDA approval2015-04-20
Generic availableYes · 6 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$61.5M in CY2024 Part D spend100K claims · 34K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.844/unit
16 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.04
Across all dosage forms in distribution.
Highest NADAC
$9.99
Wide spread — brand-strength NDCs still in market.
Plans with PA
373 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Ivabradine used for?

Ivabradine is a Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker medication tracked in Medicare Part D.

Is there a generic for Ivabradine?

Yes. 12 ANDAs filed at FDA, 6 generic manufacturers currently shipping.

How much does my plan pay for Ivabradine?

Across 329 Part D plans, Ivabradine averages $2.04/unit (NADAC). Lowest available: $0.844/unit. Highest in distribution: $9.99/unit.

Is Ivabradine on the FDA shortage list?

Ivabradine has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (16 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.